Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 8 of 123 for:    regorafenib

Regorafenib Post-marketing Surveillance

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Bayer Identifier:
First received: April 26, 2013
Last updated: January 6, 2017
Last verified: January 2017

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice.

A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Condition Intervention
Colorectal Neoplasms
Drug: BAY73-4506_Regorafenib

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib [ Time Frame: Up to 6 months ] [ Designated as safety issue: Yes ]
  • Number of patients with serious adverse events(SAEs) from the first administration of regorafenib. [ Time Frame: up to 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determination of patient's background to affect the safety and efficacy of Regorafenib using standard observational survey and follow-up survey [ Time Frame: baseline ] [ Designated as safety issue: No ]

Enrollment: 1306
Study Start Date: April 2013
Estimated Study Completion Date: March 2021
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: BAY73-4506_Regorafenib
Patients treated with Regorafenib under practical manner for colorectal cancer.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with unresectable, metastatic or recurrent colorectal cancer

Inclusion Criteria:Patients

  • who are determined to start Regorafenib/ STIVARGA treatment

Exclusion Criteria:

  • Patients who have previously received Regorafenib/ STIVARGA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01843400

Many Locations, Japan
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01843400     History of Changes
Other Study ID Numbers: 16472  STIVARGA-CRC-01 
Study First Received: April 26, 2013
Last Updated: January 6, 2017
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Bayer:
Colorectal Neoplasms

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on January 17, 2017